Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 12/20 | 0.62 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.48 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15720379 | 0.77 | TRPA1 (1.00) | TRPA1NR1H4ATM | |
| SCHEMBL15720906 | 0.75 | TRPA1 (1.00) | TRPA1KDM4EHSD17B10NR1H4ATM | |
| SCHEMBL15720555 | 0.72 | TRPA1 (0.64) | TRPA1SLC2A1PSMD14KDM4EHSD17B10 | |
| SCHEMBL1691861 | 0.72 | SLC2A1 (0.65) | TRPA1SLC2A1KDM4E | |
| SCHEMBL1691718 | 0.70 | SLC2A1 (0.49) | TRPA1SLC2A1NR1H4 | |
| SCHEMBL17718907 | 0.65 | SLC2A1 (1.00) | SLC2A1KDM4E | |
| SCHEMBL1691844 | 0.65 | SLC2A1 (0.51) | TRPA1SLC2A1KDM4E | |
| SCHEMBL5393887 | 0.65 | TRPA1 (0.47) | TRPA1KDM4EHSD17B10 | |
| SCHEMBL1691706 | 0.65 | SLC2A1 (0.51) | TRPA1SLC2A1KDM4EHSD17B10 | |
| SCHEMBL15720616 | 0.64 | TRPA1 (1.00) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394304-B2 | Imidazopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | claimed |
| EP-2920169-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-23 | — | — | EP | claimed |
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | claimed |
| WO-2014076021-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | claimed |
| US-9394304-B2 | Imidazopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2920169-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2014076021-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | QDPR, ADRB3, HRH4 | TRPA1 882/4885SLC2A1 4741/4885PSMD14 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.